Little Benefit for Etanercept-MTX Before Triple Therapy in RA

Share this content:
Little Benefit for Etanercept-MTX Before Triple Therapy in RA
Little Benefit for Etanercept-MTX Before Triple Therapy in RA

TUESDAY, May 30, 2017 (HealthDay News) -- For patients with rheumatoid arthritis, first-line etanercept-methotrexate is associated with increased costs compared with triple therapy, while providing minimal benefit, according to a cost-effectiveness analysis published online May 30 in the Annals of Internal Medicine.

Nick Bansback, Ph.D., from the University of British Columbia in Vancouver, Canada, and colleagues examined the cost-effectiveness of etanercept-methotrexate in a within-trial analysis based on 353 participants in the Rheumatoid Arthritis Comparison of Active Therapies trial, and a lifetime analysis extrapolating costs and outcomes.

The researchers found that use of etanercept-methotrexate as first-line therapy was associated with marginally more quality-adjusted life-years (QALYs) but substantially higher drug costs. Negligible differences were seen between strategies in other costs. For first-line etanercept-methotrexate and triple therapy, the incremental cost-effectiveness ratios were $2.7 and $0.98 million per QALY over 24 and 48 weeks, respectively. First-line etanercept-methotrexate was found to result in a 0.15 additional lifetime QALY in lifetime analysis; this gain would cost an incremental $77,290, resulting in an incremental cost effectiveness ratio. of $521,520 per QALY per patient.

"Considering a long-term perspective, an initial strategy of etanercept-methotrexate and biologics with similar cost and efficacy is unlikely to be cost-effective compared with using triple therapy first, even under optimistic assumptions," the authors write. Therefore, "initiating biologic therapy without trying triple therapy first increases costs while providing minimal incremental benefit."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Even Overdose Doesn't Stop Opioid Prescribing

Even Overdose Doesn't Stop Opioid Prescribing

Few receive medication-assisted treatment after hospital discharge, researchers find

NT-ProBNP-Guided Treatment No Benefit in High-Risk HFrEF

NT-ProBNP-Guided Treatment No Benefit in High-Risk HFrEF

No improvement in clinical outcomes versus usual care in heart failure and reduced ejection fraction

Oral Corticosteroids No Benefit for LRI in Non-Asthmatic Adults

Oral Corticosteroids No Benefit for LRI in Non-Asthmatic ...

No decrease in cough duration, severity for adults without asthma with lower respiratory tract symptom

is free, fast, and customized just for you!

Already a member?

Sign In Now »